Duchenne UK

MetrioPharm AG is a pharmaceutical development company based in Zurich, Switzerland, founded in 2007. The company focuses on creating drugs for chronic inflammatory diseases, including psoriasis, arthritis, and multiple sclerosis. MetrioPharm's lead product candidate, MP1032, is currently undergoing phase II clinical trials for the treatment of moderate to severe chronic plaque psoriasis. The company aims to improve the effectiveness and tolerability of therapies for these chronic conditions, with the goal of halting disease progression at early stages and significantly enhancing the healthy lifespan of patients. MetrioPharm is dedicated to developing small molecular drugs that leverage immune and metabolic modulation to address both acute and chronic inflammatory diseases.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.